Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mark W. Sherman

Reporter

Washington, DC
Advertisement
Set Alert for Articles By Mark W. Sherman

Latest From Mark W. Sherman

FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says

Informally, FDA appears open to trials that use cognition as the only primary endpoint rather than insisting that products also show benefit on the functional side.

Drug Approval Standards Neurology

Argos Says FDA Willing To ADAPT To Longer Follow-Up For Immunotherapy

Argos Therapeutics reports FDA support for its plan to continue its ADAPT trial of rocapuldencel-T for metastatic renal cell carcinoma despite a futility finding by the independent data monitoring committee.

Cancer Clinical Trials
See All
Advertisement
UsernamePublicRestriction

Register